WHAT IS CLAIMED IS:

1. A pharmaceutical composition, comprising


micronized Compound A, and/or

micronized at least one pharmaceutically acceptable salt of Compound A, and

at least one pharmaceutically acceptable excipient,

wherein the micronized Compound A and/or the micronized at least one pharmaceutically acceptable salt of Compound A has a particle size distribution (PSD) D90 value of greater than 2 µM and less than or equal to 20 µm,


wherein Compound A is *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide represented by the formula:



.

2. A pharmaceutical composition of claim 1, comprising at least one pharmaceutically acceptable excipient and micronized Compound A having a D90 value of greater than 2 µM and less than or equal to 20 µm,

wherein Compound A is *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide represented by the formula:



3. The pharmaceutical composition of claim 1 or 2, wherein the micronized Compound A is micronized Form I *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

4. The pharmaceutical composition of claim 1 or 2, wherein the micronized Compound A is micronized substantially pure Form I *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

5. The pharmaceutical composition of claim 1 or 2, wherein the micronized Compound A is micronized Form II *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.


6. The pharmaceutical composition of claim 1 or 2, wherein the micronized Compound A is micronized substantially pure Form II N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

7. The pharmaceutical composition of any one of claims 1-6, wherein the at least one pharmaceutically acceptable excipient is chosen from diluents, disintegrants, granulation binders, and glidants.

8. The pharmaceutical composition of claim 7, wherein the diluent is selected from mannitol, microcrystalline cellulose, starch, lactose, dextrin and sorbitol, the disintegrant is sodium starch glycolate, the granulation binder is polyvinylpyrrolidone, and the glidant is selected from silicon dioxide and magnesium stearate.


9. Micronized Compound A, and/or micronized at least one pharmaceutically acceptable salt of Compound A,
wherein the micronized Compound A and/or the micronized at least one pharmaceutically acceptable salt of Compound A has a particle size distribution (PSD) D90 value of less than or equal to 20 µm,

wherein Compound A is *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide represented by the formula:



.

10. The micronized Compound A of claim 9, having a D90 value of less than or equal to 20 µm,
wherein Compound A is *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide represented by the formula:



11. The micronized Compound A of claim 10, wherein the micronized Compound A is micronized Form I *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

12. The micronized Compound A of claim 10, wherein the micronized Compound A is micronized substantially pure Form I *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

13. The micronized Compound A of claim 10, wherein the micronized Compound A is micronized Form II *N*-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1*H*-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

14. The micronized Compound A of claim 10, wherein the micronized Compound A is micronized substantially pure Form II N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide.

15. The micronized Compound A of any one of claims 10-14, wherein the particle size distribution (PSD) D90 value is greater than 2 µM and less than or equal to 20 µm.

16. The pharmaceutical composition according to any one of claims 1-8 or the micronized Compound A according to any one of claims 9-15 for use in the treatment of at least one disease responsive to FGFR1 inhibition, and/or at least one disease responsive to KDR inhibition.

17. Use of the pharmaceutical composition according to any one of claims 1-8 or the micronized Compound A according to any one of claims 9-15 in the manufacture of a medicament for treatment of at least one disease responsive to FGFR1 inhibition, and/or at least one disease responsive to KDR inhibition.